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ABSTRACT 
Background: According to International Headache classification, migraine is classified in episodic 
migraine (EM) and chronic migraine (CM) based on the frequency of attacks. Medication-overuse 
headache (MOH) is a secondary chronic headache disorder defined as a frequent headache (15 days per 
month or more) induced by the overuse of analgesics. MOH occurs in patients with a previous headache 
history, usually episodic or chronic migraine. Currently the only treatment options include a 
detoxification program based on the abrupt withdrawal of overused painkillers and eventually a 
preventive treatment. Despite these therapeutic efforts, the relapse rate of MOH is high and no valid 
biomarkers are available to detect among patients who suffer from EM to CM and among chronic 
migraine those at greatest risk of develop a MOH. According to the data available, certain groups of 
people are more vulnerable to develop chronic pain conditions and poor adaptation to stress. On the basis 
of the scientific knowledge, a behavioral model of headache was proposed considering the strong 
association between pain, homeostatic imbalance and affective behavior. This pain and stress 
vulnerability is determined by genetic and non-genetic but heritable factors under the effect of 
environmental exposures as well as stochastic events during development. Differences between 
individuals’ DNA sequences can predispose toward maladaptive behaviors in many disorders comorbid 
with MOH, conferring a risk for chronic pain and by functioning as a type of molecular memory.  Several 
evidences confirmed that pain vulnerability and attitude to chronic pain sensitivity are heritable via 
genetic but also epigenetic pathways though changes in DNA expression. Epigenetic mechanisms would 
have the potential to link early life events, neuro-inflammation and brain plasticity in the aetiology of 
migraine chronification.  
Aim of the study: to identify changes in DNA methylation associated with headache chronification.   
Method: This was a pilot, longitudinal, prospective, observational, study. We enrolled patients into three 
groups: Patients with MOH, EM and healthy control without headache (HC). For MOH patients visits 
occurred at baseline (T0), at T1 for detox program, then at 2 month (T2) and 6 months (T3) after detox. 
About group of EM and HC, patients were evaluated at baseline (T0) and 6 months later (T1). At each 
follow-up visit Genomic DNA was extracted from whole blood and whole blood genome-wide DNA 
methylation profiles was analysed using the Infinium HumanMethylationEPIC Bead- Chip (Illumina)  
Results:  A total of 25 patients with MOH were enrolled at baseline (T0), 21 underwent protocol of 
withdrawal (T1), of these 19 and 18 were followed to visit T2 and T3 respectively. In the group of EM, 
20 patients were enrolled and all subjects completed the study to T1. With regard to HC, 13 subjects were 
enrolled at T0, and 11 completed study at T1. Overall at T3, 6 month later detox program, 4 patients 
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remained chronic with medication overuse (22%), while 14 (78%) were cured from overuse. Among them 
11 (61%) still fulfilled a diagnosis of chronic migraine and 3 (16%) reversed to an EM.  We compared 22 
MOH samples at T0 vs 13 HC at T0. No differentially methylated regions (DMRs) reached statistical 
significance after Benjamini–Hochberg correction for multiple test. When considering a nominal 
threshold of 0.01, we identified 721 DMRs. While most of the DMRs showed very small DNA 
methylation differences between the two groups, 29 had a delta of at least 0.05 in at least one CpG site. 
Then we then compared 22 MOH samples at T0 and 19 samples MOH at T1 and MOH samples at T0 and 
at T3, excluding those subjects (4) that at T0 were still MOH at T3: no DMR reached statistical 
significance after Benjamini–Hochberg correction.  
Discussion: Comparing MOH vs HC group, none differentially methylated regions reached statistical 
significance, nevertheless 29 Different methylated regions had a delta of at least 0.05 in at least one CpG 
site.  Among these 29 "risk DMRs " there are 4 most significant CpG site located in genes relevant for the 
possible implication with migraine chronification and drug addiction. Epigenetic alterations and mostly 
changes in DNA methylation have been previously hypothesized as a possible mechanism of migraine 
chronification. Our pilot study revealed that major DNA methylation mostly differs between MOH and 
HC. Data obtained from analysis of different methylated regions seems to support the clinical hypothesis 
of prominent role of Medication overuse in chronicization risk. Epigenetic mechanisms suggested as 
involved in migraine chronicization, play a crucial role in processes implicated in controlling dependence 
and cognitive-emotional regulation of stress. Conversely, these exploratory results lacked to detect 
differences in DNA methylation profile of MOH in response to treatments of detox and prophylaxis. Our 
results are preliminary and require then replication and validation in a larger sample. 
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INTRODUCTION 
EPISODIC AND CHRONIC HEADACHE: STATE OF THE ART 
Migraine, is a headache disorder characterized by repeated attacks of painful headache with specific 
associated features such as photophobia and phonophobia according to the International Headache 
Society (Classification of Headache Disorders, 3rd edition 2013). According to classification, it is 
classified in two main categories:  episodic migraine (EM), defined as less than 15 headache days per 
month, and chronic migraine (CM), defined as  ≥15 headache days per month for the last 3 months, with 
≥8 days per month meeting migraine criteria with or without aura.  Medication overuse headache (MOH) 
represents an aggravation of pre-existing chronic headache (Diener HC et al 2004). IHS criteria required 
regular overuse for more than 3 months of 1 or more drugs for acute and/or symptomatic treatment of 
headache  : 
1. Ergotamine, triptans, opioids or combination analgesics on 10 or more days/month  
2. Simple analgesics on 15 or more days/month   
3. Any combination of acute/symptomatic drugs on 10 or more days/ month without overuse of any single 
class alone  
The majority of MOH patients suffered from migraine or tension-type headache (TTH) as primary 
headache and rarely cluster headache (Paemeleire K et al 2008).  Overall, CM has a significant impact on 
the population, as each year, about 2.5 % of patients with EM develop new-onset CM, while it is 
estimated that MOH affects between 1% and 2% of the general population, up to 25-50% of the chronic 
headache population. (Stovner L et al 2005, Evers S et al 2011)  MOH is extremely costly both to the 
patient and to society because of absenteeism and the burden on the health care services. (Evers S et al 
2010) Recently, the Eurolight study estimated the mean per- person annual costs for MOH to €3561, 
three times the costs of migraine and more than ten times the costs of Tension type headache. (Linde M et 
al 2012) According to EFNS guidelines, treatment of MOH patients should include: patient’s education 
on the nature of the disease, on risk factors and on treatment options; withdrawal including rescue 
medication; preventive treatment and a multimodal approach including psychological support, if 
necessary (Evers S et al 2011). Recent studies confirmed not only headache frequency and acute 
medication intake, but also disability, depression and anxiety were considerably reduced in patients with 
MOH by detoxification and prophylactic treatment. (Bendtsen L et al 2014)  Actually it is generally 
agreed that an abrupt withdrawal is considered the gold standard treatment for MOH. (Evers S et al 2011) 
After an abrupt withdrawal, the patients’ headache episodes gradually decrease in frequency over a 4 to 
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12-week period. (Katsarava Z et al 2001)  The role of detoxification programs and the timing to begin 
prophylactic therapy with respect to detox program is still highly debated (Diener HC 2012, Olesen J 
2012). Although these evidences, the relapse rate in MOH after detox program remains high, especially, 
based on the duration of MOH, the amount and types of drugs overused, the coexistence of psychiatric 
disorders, and history of relapse after withdrawal to better target the treatment.  Patients with migraine as 
the primary headache, as well as patients who had overused triptans, had fewer relapses, whereas chronic 
tension-type headache, overuse of opioids and comorbid psychiatric disorders were associated with 
increased risk of relapse. Patients with a duration of MOH over 1 year, overuse of opioids or more than 1 
type of prescription medications, coexisting psychiatric disorders, or a history of relapse or unsuccessful 
withdrawal have been shown to have a poorer treatment outcome. (Rossi P et al 2009) Chiang et al. 
summarized the remission and relapse rates after discontinuation in 22 studies, with follow-ups of 2–60 
months. The relapse rate varied between 0% and 45%. Overall the majority of studies showing a relapse 
rate of 25–35%. (Chiang, C. C. et al 2015)  
PATHOPHYSIOLOGY  AND CLINICAL BIOMARKERS OF CHRONIC HEADACHE 	  
Despite experts have studied CM and MOH for long time, the biological mechanisms of headache 
chronification are poorly understood and do not exist therapeutic biomarkers enabling clinicians to act 
preventive approaches. Recent evidences suggest hypothesis that CM cannot be just a complication of 
EM but the two process coud be independent, probabily expression of separate diseases rather than one. 
(Burshtein R et al 2015) Several studies have tried to identify clinical risk factors that can worsen the 
natural history of Migraine with increased risk to evolve into CM.  Firstly it has been known that an 
excessive use of acute medication can cause headache to worsen. Prolonged exposure to pain medication 
seems to be the main force that drives MOH-related alterations in structural and functional properties of 
the brain. All pain medications, including migraine-specific (triptans and ergotamines) and nonspecific 
(analgesics, opioids) drugs, can cause MOH. Certain classes of drugs can result in MOH faster and/or 
with shorter overuse duration than others, suggesting that the pathophysiological mechanisms in MOH 
might be at least partly specific to the overused drug. (De Felice M. et al 2010) Several observations 
suggest that analgesic overuse is the cause of chronic headache, not the consequence and MOH results 
from an interaction between an excessive use of abortive medication and a susceptible patient.  Other 
factors  such as stressful events in a patient’s life, but also comorbidities such as arterial hypertension, 
early physiological or surgical menopause and psychiatric diseases (depression, anxiety and bipolar 
disorder)  have been known to promote MOH (Diener HC et al  2016).  
Possible mechanisms of chronicization include alteration of cortical neuronal excitability and central 
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sensitization involving the trigeminal nociceptive system. Cortical hyperexcitability is the main factor 
underlying the transformation of episodic migraine into chronic migraine as confirmed by results of 
electrophysiological and functional imaging studies. Chronic analgesic exposure leads to 
hyperexcitability in cortical neurons and an increase in cortical spreading depression.   Studies using 
transcranial magnetic stimulation data have demonstrated that occipital cortex is in a state of 
hyperexcitability in patients with chronic migraine (Aurora, S.K 2009). As well as evidences from 
neuroimaging studies confimed dysmodulation of the Pain System in the Brainstem:  in chronic migraine, 
there are structural and functional dysfunctions in cerebral areas localized in the brainstem and in the 
lateral and medial pain pathways. Advances technique of volumetric magnetic resonance imaging (MRI; 
voxel-based morphometry) showed reduction in the grey and white matter in brain areas of the pain 
network and increased density of the structures of the brainstem were in patients with chronic migraine 
(Aurora, S.K 2009, Chiapparini L, 2010). The results of electrophysiologic and functional imaging 
studies indicate that chronic migraine is associated with abnormalities in the periaqueductal gray matter 
(PAG) that may be progressive (Aurora, S.K 2009). Several nuclei located in this area, namely PAG, 
nucleus raphe, and locus coeruleus are known to be pivotal in the modulation of sensory information. 
Therefore, derangement of this complex network can result in abnormal sensory perception (eg, throbbing 
headache, photophobia, and phonophobia) as seen during the attacks of migraine. Chronic alteration of 
this system can lead to an increase in headache frequency (Srikiatkhachorn A, 2010) and is involved in 
sensory processing and pain (Chudler EH,1995). Similarly, clinical and preclinical studies have 
consistently demonstrated increased excitability of neurons in the cerebral cortex and trigeminal system 
after medication overuse, promoting the process of peripheral and central sensitization. These changes are 
mostly due to changes in serotonergic and dopaminergic pathways including the endocannabinoid system. 
Increased expression of excitatory cortical 5-HT2A receptors may increase the susceptibility to 
developing cortical spreading depression, an analog of migraine aura. A reduction of diffuse noxious 
inhibitory controls may facilitate the process of central sensitization, activate the nociceptive facilitating 
system, or promote similar molecular mechanisms to those involved in kindling. Low 5-HT levels also 
increase the expression and release of calcitonin gene-related peptide from the trigeminal ganglion and 
sensitize trigeminal nociceptors. Thus, derangement of central modulation of the trigeminal system as a 
result of chronic medication use may increase sensitivity to pain perception and foster or reinforce 
medication overuse headache. (Srikiatkhachorn A, 2014).  Functional imaging studies also support to the 
hypothesis of alteration in cortical excitability in MOH. Using fludeoxyglucose (F18) position emission 
tomography, Fumal et al demonstrated several areas of hypometabolism, including the bilateral thalamus, 
orbitofrontal cortex, anterior cingulate gyrus, insula/ventral striatum, and right inferior parietal lobule, in 
patients with MOH. (Fumal et al, 2006). The gray matter volume was found to be increased in the PAG, 
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bilateral thalamus, and ventral striatum, and decreased in the frontal regions, including the orbitofrontal 
cortex, anterior cingulate cortex, the left and right insula, and the precuneus. (Riederer F, 2012) Because 
these areas are involved in pain perception, these observed abnormalities suggest an alteration in pain 
modulatory networks in patients with MOH.  
 
INTER-INDIVIDUAL PAIN AND STRESS VULNERABILITY AND EPIGENETIC 
MODIFICATIONS 
A behavioural model of headache was proposed by Montagna (Montagna P, et al 2008), based on the 
association between pain, homeostatic imbalance and affective behavior. This theory is strictly linked to 
current concept of pain vulnerability. Pain is a fundamental experience comprising both sensory and 
emotional components, which in turn are intensively linked to cognitive factors such as expectations and 
previous experiences. While acute pain is biologically adaptive by signaling potential or actual tissue 
damage to evoke protective behavior, in some cases it becomes maladaptive and chronic. The nociception 
is not always synonymous with pain, which is experienced as a conscious percept, but it might trigger 
brain responses without necessarily causing the feeling of pain.  (Lee MC, et al 2009) During a migraine 
attack, the nociceptive phase is mediated by the trigeminovascular pathway  (Noseda R et al. 2011) but 
the pain conscious perception of pain occurs through a network known as ‘‘pain matrix”. (Tracey I et al. 
2007)  Within the pain matrix, the anterior cingulate cortex is involved in the affective (cognitive–
evaluative) component of pain, while the insula is situated at the interface of the cognitive, homeostatic, 
and affective systems of the human brain, providing a link between stimulus-driven processing and brain 
regions involved in monitoring the internal milieu. (Cortelli P et al. 2013) Hence “Pain matrix” is not 
standalone entity, but is a substrate continuously subject to modulation dependent upon the interplay of 
homoeostatic and environmental factors. These complex systems acts simultaneously and influence the 
individual perception of pain. (Tracey I et al. 2007)   Stressful life events, emotions, motivations, and 
consequent behaviors acting on the pain coming in turn, inducing a vicious circle of constant brain 
remodeling which influence the neuronal architecture and molecular processes of the brain structures 
involved in the perception of pain. (Ritter C  et al 2009) Several evidences confirmed that pain 
vulnerability and attitude to chronic pain sensitivity per se are heritable via genetic and epigenetic 
pathways though changes in DNA expression. There are evidence from twin and population-based studies 
that genetic risk factors can explain some of the individual differences in pain perception and the etiology 
of chronic pain conditions. Epigenetic mechanisms would have the potential to link early life events, 
neuro-inflammation and estrogen activities in the etiology of migraine and in its chronification (Montagna 
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P 2008) and pharmaco-epigenetics could be implicated in the wide spectra of different drug treatment 
responses (Montagna P 2008).  
In recent years it has become evident that epigenetic processes play an important role in a range of 
multifactorial diseases (Yan H et al.2016). Epigenetics encompasses changes to the DNA structure 
without changing the genetic code, resulting in chromatin remodelling and consequently affecting 
transcriptional potential and expression of genes. The main epigenetic modifications or ‘marks’ are post-
translational modifications of the tails of histone proteins and DNA methylation, collectively comprising 
the epigenome. Epigenetic marks are tissue specific, can be dynamic but can also be stably inherited 
through cell divisions. Therefore, epigenetic processes enable cell and developmental stage-specific 
regulation of gene expression, but also play an important role in programming lasting responses to 
environmental cues. A main epigenetic mechanism is DNA methylation, the covalent addition of a methyl 
group to the 5th carbon of cytosine residues, which is typically associated with gene silencing.  Due to the 
ability of DNA methylation changes to shift a biological system from one stable state to another, their 
implication in headache chronification is of particular interest. (Eising E et al. 2013) It has been 
hypothesized that frequent headache attacks may lower the threshold for subsequent headache attacks 
through epigenetic mechanisms resulting in a feed-for-ward loop. (Eising E et al. 2013) Similarly, 
psychological acute and chronic stress and female sex hormones, which have been implicated in migraine 
genesis, are known to exert their physiological effects partly through epigenetic mechanisms (Griffiths 
BB et al 2014, Labruijere S et al 2014). The effects of female hormones are predominantly transmitted via 
nuclear receptors that adjust epigenetic programming of their target genes (Green CD et al 2011). Sex 
hormones (estrogen, progesterone or testosterone) alter brain function. Estrogens can modulate neuronal 
activity electrophysiologically and morphologically, potentially through estrogen receptors that are 
widely distributed throughout the brain, with high concentrations in the hypothalamus (Laflamme et al., 
1998). Taken together, gonadal hormonal feedback to the hypothalamus and other brain regions (McEwen 
et al., 2012) has significant impact on behaviors or neurological adaptations through specific 
neurotransmitters (Scharfman and MacLusky, 2008). One such system is the serotoninergic system 
(Hamel, 2007). Serotonin-producing neurons are found in the mid-and hindbrain regions, and project to 
forebrain, limbic, diencephalic (rostral 5-HT nuclei), and the spinal cord (caudal 5-HT nuclei) (Bethea et 
al., 2002), all of which contain both estrogen and progesterone receptors. Thus, aside from changes that 
may influence migraine circuits per se, estrogen–5-HT interactions may influence behaviors including 
mood playing a role in chronicization. About sensitization effect, this is the result of vasodilation and the 
release of pro-inflammatory cytokines. Preliminary results showed prolonged inflammatory pain was 
shown to promote pain sensitivity by causing histone hypoacetylation at the Gad2 gene, which is involved 
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in GABAergic signaling (Zhang Z et al 2011).  Therefore, migraine-related pain may cause sensitization 
of certain pain pathways via inflammation-induced changes in epigenetic gene regulation. A role for 
epigenetics has been suggested firstly for depression and other neuropsychiatric disorders, many of them 
comorbid with MOH (such as panic, obsessive-compulsive disorders, generalized anxiety, phobia). (Peña 
CJ et al 2014, Radat F et al 2005) Interestingly, depression also shares modulatory factors with migraine, 
such as female hormones and chronic stress, the latter of which is an established risk factor for 
depression. The main proof for a role of epigenetic mechanisms in depression is evident from animal 
models for major depressive disorder that show large changes in epigenetic programming of stress related 
genes (for example, BDNF) that could be reversed by antidepressant treatment. (Wilkinson MB et al 
2009).  Finally drug addiction can be viewed as maladaptive neural plasticity that occurs in vulnerable 
individuals in response to repeated exposure to a drug of abuse. Although there are no studies in MOH, 
some evidences showed that this vulnerability is partly determined non-genetic factors which include 
environmental exposures as well as stochastic events during development which act through epigenetic 
mechanisms. (Nestler EJ. 2014)  
In recent years the technologies for studying nucleic acids have literally exploded. The reduction of 
nucleic acids sequencing costs and the availability of cost effective microarray solutions for the analysis 
of DNA methylation has favoured the implementation of epigenomic studies, in particular DNA 
methylation microarray has been thoroughly used providing new insight regarding the variability and the 
role of such epigenetic agent. DNA methylation, miRNA and histone modifications have proven to be a 
potential source of powerful and robust biomarkers. Taken together both the new genetic and epigenetic 
omic approaches have the potential to provide new molecular insight in the aetiology of migraine 
chronicization, patient stratification, and therapy. (Garagnani P et al 2015).  Recently the first genome-
wide study of DNA methylation in headache chronification was published. Several potentially implicated 
loci and processes were identified but in the combined meta-analysis the strongest associated CpG sites 
were related to SH2D5 and NPTX2, two brain-expressed genes involved in the regulation of synaptic 
plasticity. Both proteins are highly expressed in the adult human brain. H2D5 gene, encodes the SH2 
Domain Containing 5 protein which regulates synaptic plasticity through the control of Rac-GTP levels. 
The second strongest associated CpG site was 76kb downstream from the nearest gene NPTX2, which 
encodes the Neuronal Pentraxin II protein an inhibitor of excitatory synapses, through binding and 
clustering of glutamatergic AMPA receptors. (Winsvold BS et al 2017)  
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AIM OF THE STUDY 	  
Aim of the study was to identify changes in DNA methylation associated with headache chronification 
comparing healthy controls without migraine, episodic migraineurs and patients suffering from chronic 
migraine with medication overuse headache. For all selected subjects, genome-wide DNA methylation 
levels were characterized at baseline and longitudinally during follow-up.  
	   12	  
MATERIALS AND METHODS  
STANDARD PROTOCOL APPROVALS AND PATIENT CONSENTS  
The study was conducted in agreement with principles of good clinical practice and the study protocol 
was approved by the Local Ethic Committee of the local health service of Bologna, Italy. All patients 
gave their written informed consent to study participation.  
PARTICIPANTS  
Patients from the Headache Centre of IRCCS of Neurological Sciences of Bologna, Italy were recruited 
consecutively. We enrolled patients into three groups: 
- Group A: Patients with chronic migraine and medication overuse headache (MOH):  Patients who met 
criteria for MOH as defined by the International Headache Society 3rd edition (beta version) : Headache 
present on 15 or more days/month in a patient with a pre-existing headache disorder; Regular overuse for 
more than 3 months of 1 or more drugs that can be taken for acute and/or symptomatic treatment of 
headache:   
• Ergotamine, triptans, or combination analgesics on 10 or more days/month  
• Simple analgesics on 15 or more days/month   
• Any combination of acute/symptomatic drugs on 10 or more days/ month without overuse of any 
single class alone  
Exclusion criteria was opioids overuse. 
- Group B: Episodic Migraineurs: Patients suffered from episodic migraine with or without aura 
according to International Headache Society 3rd edition (beta version): we selected patients with low 
frequency of attacks (maximum 6 attacks/month). An exclusion criterion was presence of prophylaxis 
therapy at baseline.  
- Group C: Healthy controls who do no suffer form headache: Subjects were screened for headache 
disorder present or not according to the HARDSHIP questionnaire (Headache-Attributed Restriction, 
Disability, Social Handicap and Impaired Participation. HARDSHIP is a modular instrument 
incorporating demographic enquiry, diagnostic questions based on ICHD-3 beta criteria, and enquiries 
into each of the following as components of headache-attributed burden (Steiner TJ et al 2014). From 
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Hardship questionnaire we used questions number 12: “Have you ever had a headache in your lifetime?” 
and number 13 “Have you had a headache during the last 12 months?”. Were enrolled only subjects who 
responded “no” to question 13.  
Overall, all patients were eligible if they were ≥18 years of age, were able to give verbal and written 
informed consent. Exclusion criteria included pregnancy and breast-feeding, secondary headaches, history 
of any types of addiction (such as alcohol, sedative, cannabis and psychoactive substances), as well as any 
serious ongoing physical or psychiatric illness. Secondary headaches were ruled out by clinical 
examination, laboratory testing and neuroimaging studies, when indicated. 
STUDY DESIGN 
This was a pilot, longitudinal, prospective, observational, study. An exploratory GWAS longitudinal 
study of DNA methylation was performed for understanding Epigenetic gene regulatory abnormalities in 
MOH, Episodic migraineurs (EM) and Healthy Controls (HC) with the collaboration of Department of 
Experimental, Diagnostic and Specialty Medicine - Bologna University. 
Fig. 1 illustrates the study design. In Group A, MOH patients, unresponsive to prophylaxis lasted three-
month period based on clinical history and previous headache diary were enrolled at baseline (T0). At T0 
patients were educated about the MOH diagnosis and received advice to stop overused drugs and were 
asked to stop prophylaxis therapy; Education consisted in a brief explanation about the nature of the 
disease and about the consequences of too frequent intake of medication to treat headache attacks. At T1, 
patients still fulfilling the diagnosis of MOH underwent the inpatient 5-day withdrawal program (T1). 
During pharmacological withdrawal program patients received paracetamol 2000 mg at 8.00 a.m., 1000 
mg at 2.00 p.m., and 1000 mg at 8.00 p.m. Allowed rescue therapies were: metoclopramide 10 mg i.m. 
and lorazepam 1 mg or 2.5 mg cap.  T2 and T3 were follow-up visits. Overall visits occurred at baseline 
(T0), 3 months after baseline (T1), then at 2 month (T2) and 6 months (T3) after inpatient withdrawal 
program (Fig. 1). About group B and C, patients were evaluated at baseline (T0) when they were enrolled 
and 6 months later (T1). Fig. 1. A clinical diary in which patients recorded all headaches attacks and the 
drugs taken for headache during all the study period was given at the preliminary visit and checked at 
every follow-up visit. Patients recorded the number of days of headache attacks, the headache intensity 
(classified in a range from  1 = mild to 10 = severe), the number and type of painkiller used and the 
number of days treated . Healthy survey, Depressive and anxious symptoms (SF-12, Beck Depression 
scale and Beck anxiety scale) (Ware J Jr, et al 1996, Beck A 1961,  Beck A. T 1988) and degree of 
disability (Migraine Disability Assessment Score, MIDAS, D'Amico D et al 2001) were evaluated at T0, 
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T1,T2,T3 in MOH, and T0 and T1 in EM and HC . Patients were interviewed and examined by 
neurologists expert in headaches.  
MOH 
enrollment, 
Stop 
prophylaxis 
Follow up visit 
2 months after 
T1 
Follow up visit 
6 months after 
T1 
T0 T1 T2 T3 
Start 
pharmacological 
withdrawal  
3 months after T0 
MOH 
  EM 
  HC T0 T1 
Patients 
Enrollment 
Follow up visit 
6 months after  
T0 
 
Figure 1: Study design. MOH = medication overuse headache; EM= Episodic migraineurs;  
HC= Healthy controls 
	  
	  
GENOME-WIDE QUANTIFICATION OF DNA METHYLATION  
Genomic DNA was extracted from whole blood using the QIAamp DNA Mini Kit (QIAGEN) DNA was 
bisulfite-converted using the EZ DNA Methylation-Gold Kit (Zymo Research) and analysed using the 
Infinium HumanMethylationEPIC Bead- Chip (Illumina) following the manufacturer’s instructions. 
Signal intensity IDAT files were extracted using the minfi Bioconductor package. 4773 probes were 
identified as failed positions according to their detection p-value (>0.05) and were hence discarded. After 
removing the 4773 probes, Quality Control plot reported 5 samples with bad quality which were discared. 
Therefore statistical analysis was carried on  22 MOH  samples at T0, 19 at T1, 18 at T2, 18 at T3, 18 EM 
at T0 and 17 at T1, 13 HC at T0 and 11 at T1. Stratified quantile normalization was performed on beta 
values using the function preprocessQuantile implemented in the R packege minfi.  
DNA methylation differences between the different groups of samples were assessed using the analytical 
pipeline described in (Bacalini et al.2015) Briefly, we firstly classified CpG probes according to their 
genomic localization and density in the region. We identified 41356 genomic regions mapping in CpG 
islands, shores or shelves and including at least 3 probes, for a total of 254568 probes. To identify 
statistically significantly differentially methylated regions (DMRs) (regions in which multiple adjacent 
CpG probes differ in the comparison under investigation) we applied a multivariate analysis of variance 
(MANOVA) on sliding windows including three adjacent CpG sites.  
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STATISTICS  
Quantitative variables were expressed as the mean ± standard deviation (SD) while categorical variables 
were described by their absolute and/or relative frequencies. We compared categorical variables using Chi 
square test. Kruskal-Wallis Tests was performed to compare continuous variables with an asymmetrical 
(non-normal) distribution. Significance level was set at p ≤ 0.05. Data analysis was performed with 
SPSS® version 22.  
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RESULTS 
CLINICAL RESULTS 
A total of 25 patients with MOH were enrolled at baseline (T0), 21 underwent protocol of withdrawal 
(T1), of these 19 and 18 were followed to visit T2 and T3 respectively. In the group B, EM, 20 patients 
were enrolled and all subjects completed the study to T1. With regard to HC, 13 subjects were enrolled at 
T0, and 11 completed study at T1. (Fig. 2) Clinical and Demographic baseline characteristics for the 
MOH, EM and HC patients who completed the study are presented in Table 1 and 2. Of the 25 MOH 
patients enrolled, 21(84%) were females, 18 (90%) in EM and 8 (62%) in HC group; mean age ± standard 
deviation (SD) was 50 ± 9 years, 44 ± 10, 54 ± 12 (p = 0.008) in MOH, EM, HC respectively. All 
headache participants suffered from migraine without aura at onset, with a mean age at onset of 16 ± 6 
years in MOH and 17 ± 8 in EM.  Chronification age was 36 ± 9 years with duration of MOH of 14 ± 9 
years  (Table 1). In MOH group overused medications included triptans (48%), non steroidal anti-
inflammatory drugs (NSAID, 28%), paracetamol (4%) and combination analgesics (20%). Overused 
opiates ere excluded. In EM group, painkiller used included triptans (40%), NSAID (45%), paracetamol 
(5%) and combination analgesics (10%). No statistical difference was found in acute medication used 
between the two groups.  In the MOH group 15 patients  (60%) received preventive monotherapy while 
10 (15 %) received polytherapy (a combination of 2 drugs). Main prophylactic medications included anti-
epileptics (40%), beta-blockers (28%), 25 % antidepressants and 12% calcium channel blockers. The 
three groups did not differ in associated comorbidities with exception in association with depression and 
anxiety that were more prevalent in MOH patients: 16 (64%) in MOH vs EM 4 (20%) and HC 1 (7%) (p 
< 0.05). (Table 2). Table 3 summarizes comparison in number of days of headache per month, days 
treated with acute medication and total painkiller used monthly as well as intensity of pain in MOH and 
EM at baseline T0. Data confirmed days with headache/month were significant higher in MOH both at T0 
(28 ± 3) vs EM  (5 ± 1 p < 0.05). Total number of painkiller used substantiate a value significantly higher 
in MOH 48 ± 20 at T0 when compared to EM (5 ± 1, p < 0.05)  while no difference was observed in 
intensity of pain between groups. About the evaluation of disability, the average MIDAS score was 
significantly higher in MOH vs EM (96 vs 27, p = 0.002). With regard to average score of BAI and BDI, 
results showed MOH patients fulfilled the criteria for depression and anxiety disorder with statistical 
significance (p = 0.002). At baseline, physical status evaluated through SF 12 resulted significantly worse 
in MOH group compared vs EM and HC (p = 0.001), while no differences were found in Mental status. 
(Table 4)  
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With regard to treatment in MOH patients, of 25 subjects, 21 completed the detoxification protocol. 19 
were followed to visit T2 and 18 to visit T3. Patients who dropped out become unable to reach the 
headache Center for follow-up visits due to personal employment or personal reasons. In total, headache 
days reduced from 28 ± 3 to 15 ± 9 (p = 0.002) with a significant reduction in both number of days treated 
with acute medication and total numbers of painkillers/month (Table 5). No difference was observed in 
intensity of pain. A significant reduction in disability was registered by MIDAS (mean values at T0 96 vs 
61, p < 0.05) and depression score at BAI (21  ± 7 vs 15 ± 5, p < 0.05). No statistical difference was 
observed in anxiety score and evaluation of Healthy mental and Physical status. (Table 5) Overall at T3, 6 
month later detox program, 4 patients remained chronic with medication overuse (22%), while 14 (78%) 
were cured from overuse. Among them 11 (61%) still fulfilled a diagnosis of chronic migraine and 3 
(16%) reversed to an EM.   
TO 25 T1 21 T2 19 T3 18 MOH 
TO 20 T1 20 EM 
TO 11 T1 10 HC 	  
Figure 2: Flow chart of patients included in the study 
MOH EM HC p 
Gender (F, %) 21 (84%) 18 (90%) 8 (62%) 0.03 
Age (mean ± sd) 50 ± 9 44 ± 10 54 ± 12 0.008 
Age onset Headache (mean ± sd) 16 ± 6 17 ± 8  ns 
Age of Chronicization (mean ± sd)  36 ± 9 
 
Duration of MOH (mean ± sd) 14 ± 9 
 
Acute medication used  
Triptans 12 (48%) 8 (40%) ns 
NSAID 7 (28%) 9 (45%) ns 
Paracetamol 5 (20%) 1 (5%) ns 
Combination analgesic 1 (4%) 2 (10%) ns  
Table 1: Demographic and baseline clinical characteristics of the study sample. NSAID = non steroidal anti-
inflammatory drugs. 
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MOH EM HC p 
Comorbidities  
Autoimmune disease  6 (20%) 3 (15%) 2 (15%) ns 
Neoplastic disease 8 (2%) 2 (10%) 2 (15%) 
 
ns 
Anxiety and depression  16 (64%) 4 (20%) 1 (7%) < 0.05 
Insomnia 8 (36%) 2 (10%) 1 (7%) ns 
Hypertension 2 (8%) 0 2 (15%) 
 
ns 
Other disease  2 (8%) 
 
0 2 (15%) 
 
ns 
 
Table 2: Clinical Comorbidities characteristics of the study sample. 	  
	  
MOH EM p 
T0 days with headache last month 28   ±  3 5  ±  1 0.003 
T0 days treated with painkillers/last 
month 
27  ±  4 5  ±  1 0.001 
 
T0 Total number of painkiller/month 48  ±  20  5  ±  1 0.001 
 
T0 intensity of pain 7  ±  2 6  ±  1 
 
0.021 
	  
 
Table 3: Baseline characteristics of headache in MOH and EM at T0  
 
MOH EM HC p 
MIDAS (Migraine disability 
assessment score) 
 96 (46 -180) 27 (15 – 52) 0.002 
BDI (Beck depression score) 21 ± 7 
 
7 ± 5 
 
4 ± 5 
 
0.002 
BAI (Beck Anxiety score) 10 ± 8 
 
4 ± 5 
 
2 ± 5 
 
0.002 
SF 12 Health survey (Physical 
status) 
37 ± 10* 
 
46 ± 10  55 ± 5 0.001 
SF 12 Health survey (Mental 
status) 
41 ± 11 
 
47 ± 11 53 ± 6  ns 	  
Table 4: Disability, anxiety and depression baseline clinical characteristics of the study sample. 
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T0 (25) T1(20) T2 (19) T3 (18) p 
Days with 
headache last 
month 
 
28   ±  3 
 
27  ± 5 
 
19  ±  9 
 
15  ±  9  
 
0.002 
Days treated with 
painkillers/last 
month 
 
27  ±  4 
 
26  ±  5 
 
15  ±  10 
 
15  ±  9  
 
0.001 
Total number of 
painkiller/month 
 
48  ±  20  
 
42  ±  18 
 
18  ±  18  
 
14  ±  13 
 
0.001 
 
Intensity of pain 
 
7  ±  2 
 
7  ±  1 
 
6  ±  2 
 
6  ±  2 
 
ns 
MIDAS (mean)   96 (46 -180) 
 
61 ( 30 – 115) < 0.05 
BDI (Beck 
depression score) 
 
21  ±  7 
 
15  ±  5 
 
< 0.05 
 
BAI (Beck Anxiety 
score) 
 
10  ±  8 
 
8  ±  7 ns 
SF 12 Health 
survey (Physical 
status) 
 
37  ±  10 
 
40  ± 8  
 
ns 
SF 12 Health 
survey (Mental 
status) 
 
41  ±  11 
 
43  ±  10 
 
ns 	  
Table 5: Clinical Characteristics of MOH patients at baseline and during follow-up after detox program 
	  	  
 
RESULTS OF GENOME-WIDE QUANTIFICATION OF DNA METHYLATION  
We used the Infinium MethylationEPIC BeadChip to evaluate whole blood genome-wide DNA 
methylation profiles of the subjects included in the study. 
First, we conducted principal component analysis to identify major traits of variation between samples. 
No clear separation between the groups was observed neither along the first component or the second 
component (Figure 3).  
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Figure 3: PCA on DNA methylation values (beta values) from the samples included in the study. 
 
To identify subtler epigenetic differences underling the effect of the pathology and the treatment, we then 
compared the three groups focusing on the following comparisons:  
1. MOH T0 vs HC T0 
2. MOH T0 vs MOH T1 
3. MOH TO vs MOH T3 
In these comparisons, we focused on the identification of differentially methylated regions (DMRs), that 
is genomic traits including multiple adjacent CpG sites that are concordantly affected by the phenotype 
under investigation. Compared to the analysis of single CpG sites, this approach has been demonstrated to 
be more effective in identifying biologically relevant epigenetic patterns. The discovery of the DMRs was 
performed using the analytical pipeline described in Bacalini et al. 2015, using as input only the CpG sites 
located in CpG islands and surrounding regions (shores and shelves) associated to a gene. 
 
 
1. T0 MOH vs HC 
First, we compared 22 MOH samples at T0 vs 13 HC at T0. No DMR reached statistical significance after 
Benjamini–Hochberg correction for multiple test. When considering a nominal threshold of 0.01, we 
identified 721 DMRs. While most of the DMRs showed very small DNA methylation differences 
between the two groups, 29 had a delta of at least 0.05 in at least one CpG site (Table 6). Of these, 2 
DMRs mapping in COMTD1 and ACSF3 genes had at least 2 adjacent CpG sites with a DNA 
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methylation difference between MOH T0 and HC T0 of at least 0.05 (Figure 4). 
To evaluate the capability of the 29 DMRs to distinguish HC T0 and MOH T0 samples, we performed a 
multidimensional scaling on the DNA methylation values of the most significant CpG site within each 
DMR. As shown in Figure 5, the MOH DNA methylation signature is not able to completely distinguish 
the disease from healthy controls, although a trend towards a separation is observed.  
Finally, we considered the DNA methylation of the 29 DMRs in EM samples at T0. Interestingly, for 
many of the DMRs, EM displayed DNA methylation values intermediate between HC and MOH (see 
Figure 6 for an example). Accordingly, in the MDS EM tended to cluster between HC and MOH (Figure 
7). 
 
2. MOH T0 vs MOH T1 and vs MOH T3 
We then compared 22 MOH samples at T0 and 19 samples MOH at T1. Also in this case no DMR 
reached statistical significance after Benjamini–Hochberg correction for multiple test. When considering 
a nominal threshold of 0.01, we identified 783 DMRs, but only 1 of them, located in the island of the 
RHOV gene, showed a DNA methylation difference of at least 0.05 between the two groups (Figure 8).  
 
3. We compared MOH samples at T0 and at T3, excluding those subjects (4) that at T0 were still MOH at 
T3. As in the previous analysis, no DMR reached statistical significance after Benjamini–Hochberg 
correction, and of the 461 DMRs with a nominal p-value lower than 0.01 only 1, mapping in the island of 
NBL1/MINOS1 gene, had a CpG site with a DNA methylation difference of at least 0.05 between the two 
groups (Figure 9). 
Nor RHOV nor NBL1 genes show significant differences between MOH at T0 and HC at T0 (Figures 8 
and 9). For the significant CpG sites in the genes RHOV and NBL1 we also evaluated the longitudinal 
changes in DNA methylation at T0, T1 and T3 in the subjects that at T3 changed to chronic or episodic 
(red lines) and in those that at T3 were still MOH (black lines). However, no clear trend towards 
hypermethylation or hypomethylation was observed (Figures 10 and 11).  
 
Finally, we assessed if the 29 DMRs selected in the comparison MOH at T0 vs HC at T0 were included in 
the list of DMRs in the comparisons MOH at T0 vs MOH at T1 and MOH at T0 vs MOH at T3. Only 1 
DMR, the one mapping in the island of the gene IER3, was hypermethylated in MOH at T1 compared to 
MOH at T1 (p-value=0.0038, DNA methylation difference=0.04) (Figure 12). 
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DMR GeneName p-value MOH 
respect 
to HC 
Gene function 
chr8:10586613-
10586886*Island 
SOX7 8.06E-05 HYPO Family of transcription factors involved in the 
regulation of embryonic development 
chr4:111539906-
111540127*S_Shelf 
PITX2 0.000189786 HYPER Acts as a transcriptional regulator involved in basal 
and hormone-regulated activity of prolactin.  
 
chr6:127664192-
127664755*Island 
ECHDC1 0.000724248 HYPER Ethylmalonyl-CoA Decarboxylase 1 is a Protein 
Coding gene. Among its related pathways are 
Propanoate metabolism and Fatty Acid Biosynthesis 
chr10:76993892-
76995953*S_Shore 
COMTD1 0.000903274 HYPER Catechol-O-methyltransferase is important in the 
metabolism of catecholamines, including the 
neurotransmitters dopamine, epinephrine, and 
norepinephrine. 
chr2:135475698-
135476993*Island 
TMEM163 0.001022101 HYPER Transmembrane Protein 163) is a Protein Coding 
gene. May bind zinc and other divalent cations and 
recruit them to vesicular organelles. 
chr13:114774812-
114775134*Island 
RASA3 0.001214778 HYPER Encodes a protein that binds inositol 1,3,4,5-
tetrakisphosphate and stimulates the GTPase activity 
of Ras p21 
chr5:131607018-
131607889*Island 
PDLIM4 0.001412643 HYPO Encodes a protein which may be involved in bone 
development. 
chr19:18543828-
18549161*Island 
ISYNA1 0.001886107 HYPO Encoded protein plays a critical role in the myo-
inositol biosynthesis pathway. Diseases associated 
Whipple Disease. 
chr20:23330636-
23332046*Island 
NXT1 0.001956097 HYPO The protein encoded by this gene is located in the 
nuclear envelope. It has protein similarity to nuclear 
transport factor 2. Diseases associated with NXT1 
include St. Louis Encephalitis 
chr19:44645494-
44646069*N_Shore 
ZNF234 0.002092452 HYPER ZNF234 (Zinc Finger Protein 234) is a Protein 
Coding gene. Among its related pathways are nucleic 
acid binding and transcription factor activity, 
sequence-specific DNA binding. 
chr12:95941906-
95942979*Island 
USP44 0.002234688 HYPO Encodes a protease that functions as a 
deubiquitinating enzyme. It  is thought to help 
regulate the spindle assembly checkpoint by 
preventing early anaphase onset. 
chr6:30071225-
30071428*S_Shelf 
TRIM31;TRIM31-AS1 0.002395454 HYPER Encodes a protein that functions as an E3 ubiquitin-
protein ligase. This gene shows altered expression in 
certain tumors and may be a negative regulator of 
cell growth.  
chr12:72665683-
72667551*S_Shore 
TRHDE;TRHDE-AS1 0.002973925 HYPER Encodes a member of the peptidase M1 family, an 
extracellular peptidase that specifically cleaves and 
inactivates the neuropeptide thyrotropin-releasing 
hormone 
chr1:231003631-
231004655*Island 
C1orf198 0.003147764 HYPO Chromosome 1 Open Reading Frame 198) is a 
Protein Coding gene 
chr3:62304514-
62304780*Island 
PTPRG-AS1;C3orf14 0.003181439 HYPO Encodes a member of the protein tyrosine 
phosphatase (PTP) family. PTPs are known to be 
signaling molecules that regulate a variety of cellular 
processes including cell growth, differentiation, 
mitotic cycle, and oncogenic transformation. 
chr14:51410614-
51411464*S_Shore 
PYGL 0.003407722 HYPO Encodes a homodimeric protein that catalyses the 
cleavage of alpha-1,4-glucosidic bonds to release 
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glucose-1-phosphate from liver glycogen stores. 
Humans have three glycogen phosphorylase genes 
that encode distinct isozymes that are primarily 
expressed in liver, brain and muscle, respectively. 
chr2:201450526-
201451027*Island 
AOX1 0.004314493 HYPO Aldehyde oxidase produces hydrogen peroxide and, 
under certain conditions, can catalyze the formation 
of superoxide. 
chr16:11348541-
11350803*Island 
SOCS1 0.004627827 HYPO Encodes a member of the STAT-induced STAT 
inhibitor (SSI). SSI family members are cytokine-
inducible negative regulators of cytokine signaling.  
chr12:132603367-
132603646*N_Shelf 
EP400NL 0.00496126 HYPER EP400NL (EP400 N-Terminal Like) is a Pseudogene 
chr16:89167763-
89167991*S_Shore 
ACSF3 0.005537377 HYPO Encodes a member of the acyl-CoA synthetase 
family of enzymes that activate fatty acids by 
catalyzing the formation of a thioester linkage 
between fatty acids and coenzyme A. 
chr4:57521621-
57522703*S_Shore 
HOPX 0.005766163 HYPER Encodes a homeodomain protein that lacks certain 
conserved residues required for DNA binding. It was 
reported that choriocarcinoma cell lines. 
chr7:99063423-
99063624*S_Shore 
ATP5J2;ATP5J2-
PTCD1 
0.006142224 HYPER Encodes ATP Synthase, H+ Transporting, 
Mitochondrial Fo Complex Subunit F2)  
 
chr6:30710307-
30712440*Island 
IER3 0.006796733 HYPER Involeved in the protection of cells from Fas- or 
tumor necrosis factor type alpha-induced apoptosis. 
chr17:43393891-
43394938*Island 
MAP3K14 0.006812384 HYPO Encodes mitogen-activated protein kinase kinase 14, 
which is a serine/threonine protein-kinase. It 
participates in an NF-kappaB-inducing signalling 
cascade common to receptors of the tumour-
necrosis/nerve-growth factor (TNF/NGF) family and 
to the interleukin-1 type-I receptor. 
chr11:45686160-
45687495*Island 
CHST1 0.007419375 HYPO Encodes a member of the keratin sulfotransferase 
family of proteins. The encoded enzyme catalyzes 
the sulfation of the proteoglycan keratin.  
chr12:110433797-
110434205*Island 
GIT2 0.008816633 HYPO Encodes a member of the GIT protein family, which 
interact with G protein-coupled receptor kinases and 
possess ADP-ribosylation factor (ARF) GTPase-
activating protein (GAP) activity. GIT proteins traffic 
between cytoplasmic complexes, focal adhesions, 
and the cell periphery, 
chr17:1952919-
1962328*Island 
HIC1;MIR132;MIR212 0.009069263 HYPO This gene functions as a growth regulatory and tumor 
repressor gene. Hypermethylation or deletion of the 
region of this gene have been associated with tumors 
and the contiguous-gene syndrome, Miller-Dieker 
syndrome 
chr2:25354283-
25354777*Island 
EFR3B 0.00939227 HYPO EFR3B probably acts as the membrane-anchoring 
component. 
chr10:77155128-
77169600*Island 
ZNF503-AS2 0.009643908 HYPO Is an RNA Gene. 
 
Table 6: DMRs sites which showed significant methylation differences (delta of at least 0.05) in at least one CpG site comparing 22 
MOH samples at T0 vs 13 HC at T0. Bold refers to most relevant genes.	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Figure 4; DNA methylation profile of COMTD1 and ACSF3 DMRs in HC and MOH at T0. 
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Figure 5: MDS of HC and MOH at T0 samples calculated on DNA methylation values of the selected 29 DMRs 
between HC and MOH at T0. 
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Figure 6: DNA methylation profile of COMTD1 and ACSF3 DMRs in HC, MOH and EM at T0. 
 
−0.2 0.0 0.2 0.4 0.6
−0
.2
−0
.1
0.
0
0.
1
0.
2
0.
3
0.
4
mds[,1]
m
ds
[,2
]
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
ESA_T0
HC_T0
MOH_T0
M_T0 
 
Figure 7: MDS of HC, MOH and EM at T0 samples calculated on DNA methylation values of the selected 29 
DMRs between HC and MOH at T0. 
	   26	  
	  
 
●
HC_T0 MOH_T0 MOH_T1 MOH_T3 MOH_T3_MOH
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
cg20264088 RHOV
DN
A 
m
et
hy
lat
ion
 
Figure 8: DNA methylation of cg20264088 in the Island chr15:41165847-41166571 of RHOV gene 	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Figure 9: DNA methylation of cg03048314 in the Island chr1:19970255-19971923 of NBL1 gene 
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  Figure	   10:	   DNA methylation profile of cg20264088 in the Island chr15:41165847-41166571 of RHOV gene, 
assessed longitudinally at T0, T1 and T3. 
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Figure 11:  DNA methylation profile of cg03048314 in the Island chr1:19970255-19971923 of NBL1 gene, assessed 
longitudinally at T0, T1 and T3. 
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Figure 12: Figure 10: DNA methylation of cg16331823 in the Island chr6:30710307-30712440 of IER3 gene 
	   29	  
DISCUSSION 
The main aim of this study was to analyse whole blood genome-wide DNA methylation profiles to 
identify markers of migraine chronicization. Using a prospective and longitudinal case-control design, 
DNA methylation patterns in the peripheral blood were examined across the genome comparing patients 
affected from chronic migraine with medication overuse headache versus patients with episodic migraine 
and healthy controls headache free. Comparing MOH vs HC group, none differentially methylated 
regions reached statistical significance after correction for multiple test considering a nominal threshold 
of 0.01. Nevertheless most of the DMRs showed very small DNA methylation differences between the 
two groups, 29 had a delta of at least 0.05 in at least one CpG site.  Among these 29 "risk DMRs " there 
are 4 most significant CpG site located in genes relevant for the possible implication with migraine 
chronification and drug addiction. One of the most significant CpG site is at the chr10:76993892 island, 
which maps in the COMT (catechol-O-methyltransferase) gene and resulted hypermethylated in MOH. 
The COMT gene encodes the COMT enzyme protein that breakdowns neurotransmitters, such as 
dopamine, epinephrine, and norepinephrine important enzymes produced by many tissues included nerve 
cells. The COMT enzyme plays a crucial role in dopamine degradation. In the brain, COMT is 
particularly important in the prefrontal cortex, a region involved with personality, planning, inhibition of 
behaviors, abstract thinking, emotion, and working (short-term) memory. The dopaminergic reward 
system acts an important role in substance use and addiction (Robinson & Berridge 1993) and frequent 
substance abuse is associated with altered dopamine levels in the brain reward system (Wanat MJ et al. 
2009). Studies on genetic variation suggest COMT hyperactivity in substance users (Beuten et al. 2006) 
From  the studies in general population, we know nicotine dependence was related to higher MB-COMT 
promoter methylation, suggesting lower COMT gene activity and thus less dopamine degradation in 
smokers (Xu Q. et al. 2010). In schizophrenia patients, alcohol use was associated with increased MB-
COMT promoter methylation (Abdolmaleky et al. 2006). Recent study showed that methylation of the 
MB- COMT promoter was associated with non-daily smoking in adolescents. (Van der Knaap LJ  et al 
2014). Although studies on genetic variation suggest COMT hyperactivity in substance users, there are 
still few preliminary studies about the association between COMT gene methylation and substance 
abusers with controversial results.  
In addition to its involvement in drug abuse mechanisms, COMT gene has been studied as a candidate 
gene for both neuropsychiatric illness and cognitive dysfunction, moreover a functional SNP in codon 
158 (Val158Met) of COMT has been shown to modulate pain perception and contribute to differences of 
pain perception (Zubieta JK, et al. 2003) Evidences from animal and human studies suggests that hyper- 
and hypo- dopaminergic states contribute to mania and depression respectively (Pathak G et al 2015).  A 
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recent review which analyses the interactions between variation in candidate genes and environmental 
factors in the aetiology of schizophrenia and bipolar disorder. Authors found that polymorphisms in 
COMT were among the most significant involved in interaction with early life stress and dependence and 
consequently able to influencing disease outcome. (Misiak B et al 2017) On the same line, a recent study 
confirmed epigenetic modulation of the expression of the COMT Val158Met polymorphism and 
subsequent effects on the relationship between traumatic life events and cognition in schizophrenia. 
(Green MJ et 2014). Beside COMT, in our study GIT2 resulted hypomethyled at CPG site 
chr12:110433797-110434205*Island. GIT2 encodes a member of the GIT protein family, which interact 
with G protein-coupled receptor kinases and possess ADP-ribosylation factor (ARF) GTPase-activating 
protein (GAP) activity. GIT proteins regulate cytoskeletal dynamics and participate in receptor 
internalization and membrane trafficking. This gene has been shown to repress lamellipodial extension 
and focal adhesion turnover, and is thought to regulate cell motility. GIT2 is one of the hypermethylated 
genes recently associated to increased schizophrenia susceptibility (LEE SA. Et al 2016).  Another 
rilevant CpG site is chr19:44645494-44646069*N_Shore which maps  in ZNF234 gene and encodes for a 
Zinc Finger Protein.  ZNF differential gene expression in peripheral blood cells from bipolar disorder 
patients had been previously reported for some of the risk genes identified, 
including ZNF641and ZNF234, members of the zinc-finger family of genes, of which ZNF804A has been 
associated with bipolar disorder and schizophrenia in genome-wide association study. Although most of 
the risk genes had not been previously shown to directly confer risk for bipolar disorder, many of them 
are within pathways previously implicated in bipolar disorder. (Hess JL et al 2015) Finally, with regard to 
CPG site chr16:11348541-11350803*Island which maps in the gene SOCS1, a recent study shows that 
loss of balance among various members of the SOCS family proteins may contribute to pathophysiology 
of multiple sclerosis. (Toghi M. et al 2017) SOCS1 encodes a member of the STAT-induced STAT 
inhibitor (SSI), a cytokine-inducible negative regulators of cytokine signalling. These evidences 
confirmed its involvement in differentiation, maturation and survival of a wide range of cells, including 
cells of the immune system and suggested a possible role in different cerebral process included migraine 
chronification.   
Although it remains unclear whether psychiatric comorbidities are risk factors for or consequences of 
MOH, depression and anxiety are more common in MOH patients than in people with episodic. (Diener 
HC et al 2016) In our sample results from BAI and BDI score confirmed MOH patients fulfilled the 
criteria for depression and anxiety disorder with statistical significance with respect to EM and HC. 
Moreover an association has also been described for MOH and subclinical obsessive-compulsive 
disorders and mood disorders. (Diener HC et al 2016)  
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Overall these four differently methylated regions resulted relevant because located in genes involved in 
drug addiction mechanisms and neuropsychiatric illness comorbid with MOH and for their implication in 
mechanisms of autoimmune control. Moreover, although preliminary, these evidences stand out the value 
of epigenetic modulation in expression of COMT gene and suggesting its role in inducing an increased 
susceptibility to develop MOH. After all, several evidences from pharmacogenomics studies showed that 
The Val (108/158) Met variation of the COMT gene is among the most studied polymorphisms associated 
with response to antidepressants treatment in patients with major depressive disorder. (Biernacka JM et al 
2015).  Noteworthy according to one study, patients with MOH who are rs4680A homozygous or carry 
the rs4680A– rs6269A haplotype are at a lower risk of relapse within the first year after successful 
detoxification than are individuals with other COMT genotypes (Cargnin, S. et al.2014).  In our sample, 
analysis of comparison in MOH group between T0 and T3 (6 month after detox treatment) considering 
only patients cured from medication overuse (EM and Chronic Migraineurs without Medication overuse) 
did not revealed statistical difference in methylated regions  included CPG site located in COMT gene. 
The only CpG site with a DNA methylation difference of at least 0.05 between T0 and T3 in the two 
subgroups mapping in the island of NBL1/MINOS1 gene. NBL1 encodes for the neuroblastoma 1 a 
protein which acts as BMP (bone morphogenetic protein) involved in growth and development and linked 
to homonym disease. To confirm at CpG sites in the gene NBL1, longitudinal analysis of changes in 
DNA methylation at T0, T1 and T3 in the subjects that at T3 changed to chronic or episodic and in those 
that at T3 were still MOH did not detect any difference. As well as comparison conducted between MOH 
patients at T0 and T1 in order to detect differences in DNA methylation profile associated with 
prophylaxis therapy did not find statistical significance in relevant different methylated regions. Although 
in our study the rate of patients cured from MOH was in line with data from literature, (Chiang, C. C. et al 
2015) we hypothesized the small number of sample resulted in limited statistical power. This datum may 
have influenced detected differences in DNA methylation levels due to treatment in both conditions. With 
regard to differences in DNA methylation profile due to prophylaxis, apart form small sample, it cannot 
even be excluded a time-depending effect. In our study design, prophylaxis were stopped for three months 
before starting detox program. It remains to consider the hypothesis that a period longer that three months 
would be necessary to detect differences in DNA methylation due to prophylaxis treatment of MOH 
profile. To our knowledge no previous studies analysed changes in DNA methylation with respect to two 
treatments approved in MOH (detox and prophylaxis therapy). Due to the limit of this exploratory study, 
although results of this study did not detect any differences in DNA methylation profile in MOH in 
response to treatments, we suggest it is necessary to extend the sample size to increase statistical 
significance and replicate the study in order to confirm or to argue reasons for the absence of these 
evidences. 
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Epigenetic alterations and mostly changes in DNA methylation have been previously hypothesized as a 
possible mechanism of migraine chronification (Eising E et al 2013).  Cortical spreading depression has 
been associated to increased neuronal activity which can result in DNA methylation changes in brain- 
specific genes related to neuronal plasticity (Guo JU et al 2011). Consequently the suggested hypothesis 
is that neuronal activity can cause epigenetic changes altering synaptic plasticity and the frequent 
migraine attacks in a feed-forward loop may promote stable epigenetic changes which altering synaptic 
plasticity supporting migraine chronification. Recent evidences supporting this hypothesis, come from the 
study of Winsvold and colleagues (Winsvold BS et al 2017). Our study seems to provide some evidences 
supporting a role in MOH of epigenetic processes involved in aberrant immune-inflammatory responses 
and deregulation of dopaminergic neurotransmission theoretically implied in mechanisms of brain 
plasticity which control drug addiction and cognitive-emotional processes. From this point of view drug 
addiction can be viewed as maladaptive neural plasticity that occurs in vulnerable individuals in response 
to repeated exposure to a drug of abuse. (Nestler EJ 2013), and it well known that Medication overuse is a 
major risk factor for headache chronification (Rossi P et 2009). Notably, unlike previous studies, we did 
not find statiscal differences in the methylation profile between patients with MOH and patients with EM 
(data do not shown). Interestingly, a subanalysis of the DNA methylation of the 29 DMRs in EM samples 
at T0 displayed, for many of the DMRs, values of DNA methylation intermediate between HC and MOH 
suggesting EM tended to cluster between HC and MOH.  
The major strengths of this study include the genome-wide assessment of DNA methylation sites, the 
clinical longitudinal follow-up that allow confirming the clinical diagnosis and the correct selection of the 
patients. To these regard it was notable the comparison of DNA methylation level with a group of healthy 
controls whitout headache which confirmed themselves headache free after 6 months of follow-up. On the 
other hand our study has clear limitations. First, this is a preliminary longitudinal analysis with a small 
sample size. Accordingly, our results must be seen as exploratory and one needs to consider that 
statistically empowered studies are now required for replication and validation. Moreover our search for 
different methylated regions was performed in whole blood that do not necessarily represent a proxy of 
brain expression and methylation. Nevertheless, there is evidence showing good concordances between 
DNA methylation levels in blood with DNA methylation levels in one or more brain regions. (Davies MN 
et al 2012). Finally, in order to detect reproducible longitudinal epigenetic effects,
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data at T0, T1 and T3 should be re-analysed using a statistical approach that specifically assess 
intraindividual changes in DNA methylation of adjacent CpG sites. 
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CONCLUSION 
In summary, our pilot study revealed that peripheral DNA methylation mostly differs between MOH and 
HC. Data obtained from analysis of different methylated regions seems to support the clinical hypothesis 
of prominent role of Medication overuse in chronicization risk. Epigenetic mechanisms hypothesized to 
be involved in migraine chronicization, play a crucial role in processes implicated in controlling 
dependence and cognitive-emotional regulation of stress. Conversely, these exploratory results lacked to 
detect differences in DNA methylation profile of MOH in response to treatments of detox and 
prophylaxis. Our results are preliminary and require replication and validation in a larger sample, 
especially considering that chronic migraine is a complex and multidimensional disorder in which several 
biochemical, cognitive, behavioral and neuro-structural pattern contribute simultaneously. 
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